Clinical Evaluation of the Efficacy of a Dietary Supplement Claiming Anti-aging Properties and UV-protection
NCT ID: NCT06571409
Last Updated: 2025-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2024-09-25
2025-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of a Longevity Supplement on Aging and Photoaging
NCT05262036
A Dietary Supplement Examined for Anti-ageing Effects
NCT06714162
A Study to Assess the Impact of a Nutritional Supplement on Wellbeing and Nutrient Absorption
NCT06749808
Antioxidant Effect of Aged Garlic Extract
NCT02019368
Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo
NCT06727292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study foresees 56 days of products intake. Evaluations of the parameters under study are performed at baseline, after 14, 28 and 56 days of products consumption.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coriander Seed Oil - Dose 1
Dietary supplement - Coriander Seed Oil dose 1
Coriander Seed Oil - Dose 1
The study foresees the intake of 1 capsule per day during 56 days
Coriander Seed Oil - Dose 2
Dietary supplement - Coriander Seed Oil dose 2
Coriander Seed Oil - Dose 2
The study foresees the intake of 1 capsule per day during 56 days
Placebo
Dietary supplement - Placebo
Placebo
The study foresees the intake of 1 capsule per day during 56 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coriander Seed Oil - Dose 1
The study foresees the intake of 1 capsule per day during 56 days
Coriander Seed Oil - Dose 2
The study foresees the intake of 1 capsule per day during 56 days
Placebo
The study foresees the intake of 1 capsule per day during 56 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasian ethnicity
* Age between 35 and 65 years old (extremes included)
* Phototype I to III (with all skin types without any specific repartition)
* Visible Crow's feet wrinkles (\> 2 according to Skin Aging Atlas - Caucasian Type - Bazin Roland) and mild to moderate skin slackness at cheek level (grade 1-3 - internal clinical scale)
* Subjects who have not been recently involved in any other similar study (at least 1 month of wash-out)
* Subjects registered with health social security or health social insurance
* Subjects having signed the Informed Consent Form (ICF) and Privacy Policy for their participation in the study and a photograph authorization
* Subjects able to understand the language used in the investigation center and the information given
* Subjects able to comply with the protocol and follow protocol constraints and specific requirements
* Willingness to use during all the study period only the product to be tested
* Willingness not to use similar products that could interfere with the expected product effect to be tested (e.g. with antiaging or soothing or UV protection efficacy)
* Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.)
* Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial
* Subjects who have not sun exposure (both natural or artificial) for at least two months
* Subjects who accept not to expose in intensive way to UV rays during the whole study duration
* Subjects who have not been involved in any sun test (for SPF evaluation) or tests that provide skin irradiation since less than two months
Exclusion Criteria
* Subject who is deprived of freedom by administrative or legal decision or under guardianship
* Subject admitted in a sanitary or social facilities
* Subject who is planning an hospitalization during the study
* Subjects under treatment with food supplements which could interfere with the functionality of the product under study
* Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (if women of childbearing potential)
* Subject has started or changed estrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study
* Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Subjects under radiotherapy, chemotherapy at any time
* Subject having a skin condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Pharmacological treatments (topic or systemic) known to interfere with skin metabolism/physiology
* Subjects under locally pharmacological/non-pharmacological treatment applied on the skin area monitored during the test
* Subject with known or suspected sensitization to one or more test formulation ingredients
* Subjects considered as not adequate to participate to the study by the investigator
* Adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated)
* Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function
35 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seppic
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eleonora SpartÃ
Role: STUDY_DIRECTOR
Complife Italia S.r.l
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complife Italia S.r.l
San Martino Siccomario, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IT0003160/24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.